Literature DB >> 15664490

Heterogeneous vancomycin-resistant Staphylococcus aureus (hetero-VISA) in Singapore.

Li-Hwei Sng, Tse Hsien Koh, Grace Chee Yeng Wang, Li-Yang Hsu, Maria Kapi, Keiichi Hiramatsu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15664490     DOI： 10.1016/j.ijantimicag.2004.11.001

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN： 0924-8579            Impact factor:   5.283


× No keyword cloud information.
  7 in total

1.  Decreased vancomycin susceptibility in Staphylococcus aureus caused by IS256 tempering of WalKR expression.

Authors:  Christopher R E McEvoy; Brian Tsuji; Wei Gao; Torsten Seemann; Jessica L Porter; Kenneth Doig; Dung Ngo; Benjamin P Howden; Timothy P Stinear
Journal:  Antimicrob Agents Chemother       Date:  2013-04-29       Impact factor: 5.191

2.  Cartography of methicillin-resistant S. aureus transcripts: detection, orientation and temporal expression during growth phase and stress conditions.

Authors:  Marie Beaume; David Hernandez; Laurent Farinelli; Cécile Deluen; Patrick Linder; Christine Gaspin; Pascale Romby; Jacques Schrenzel; Patrice Francois
Journal:  PLoS One       Date:  2010-05-20       Impact factor: 3.240

3.  Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore.

Authors:  R K C Fong; J Low; T H Koh; A Kurup
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-04-22       Impact factor: 3.267

Review 4.  Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications.

Authors:  Benjamin P Howden; John K Davies; Paul D R Johnson; Timothy P Stinear; M Lindsay Grayson
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

5.  Inhibition of growth of highly resistant bacterial and fungal pathogens by a natural product.

Authors:  Rand R Hafidh; Ahmed S Abdulamir; Law Se Vern; Fatimah Abu Bakar; Faridah Abas; Fatemeh Jahanshiri; Zamberi Sekawi
Journal:  Open Microbiol J       Date:  2011-08-16

6.  Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis.

Authors:  Aref Shariati; Masoud Dadashi; Majid Taati Moghadam; Alex van Belkum; Somayeh Yaslianifard; Davood Darban-Sarokhalil
Journal:  Sci Rep       Date:  2020-07-29       Impact factor: 4.379

Review 7.  Systematic Review and Meta-Analysis of the Epidemiology of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates.

Authors:  Shanshan Zhang; Xiaoxi Sun; Wenjiao Chang; Yuanyuan Dai; Xiaoling Ma
Journal:  PLoS One       Date:  2015-08-19       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.